India has emerged as a global pharmaceutical hub, often referred to as the “Pharmacy of the World” due to its high-volume, low-cost production of medicines. Within the country, one city stands out as the epicenter of pharmaceutical innovation, manufacturing, and exports — Hyderabad, the capital of Telangana. Over the decades, Hyderabad has earned the prestigious title of the “Pharma Capital of India”, owing to its robust infrastructure, strategic policies, and a thriving ecosystem of pharmaceutical companies.
The Rise of Hyderabad as a Pharmaceutical Powerhouse
Hyderabad’s transformation into the pharmaceutical capital began in the 1970s and 1980s, when public sector units like Indian Drugs and Pharmaceuticals Limited (IDPL) laid the foundation for large-scale drug manufacturing. With time, the city attracted private enterprises and multinational corporations due to its favorable policies, abundant talent, and scientific research institutions.
Today, Hyderabad is home to over 800 pharmaceutical companies, making it a central player in India’s pharmaceutical production and export landscape.
Genome Valley: The Heart of Biotech and Pharma
One of the most significant contributors to Hyderabad’s pharmaceutical identity is the development of Genome Valley, India’s first and largest biotechnology cluster. Spread over 600 square kilometers, Genome Valley hosts a wide range of research labs, pharmaceutical companies, biotech firms, and academic institutions.
Companies located here are involved in everything from drug discovery and clinical trials to biotechnology research and vaccine development. The ecosystem has attracted global giants like Novartis, GlaxoSmithKline, Johnson & Johnson, and domestic leaders like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Biological E.
COVID-19 and Hyderabad’s Global Role
Hyderabad’s role as the Pharma Capital of India became even more evident during the COVID-19 pandemic. The city emerged as a vaccine manufacturing hub, producing millions of doses not only for India but for countries across the world. Companies like Bharat Biotech, which developed Covaxin, and Biological E., which contributed significantly to vaccine supply, are headquartered in Hyderabad.
This response reinforced Hyderabad’s image as a life sciences hub with global capabilities.
Research, Talent, and Infrastructure
Hyderabad’s pharmaceutical strength is not limited to manufacturing. The city is a hub for scientific research and drug innovation. Institutions like the Centre for Cellular and Molecular Biology (CCMB), Indian Institute of Chemical Technology (IICT), and National Institute of Pharmaceutical Education and Research (NIPER) provide critical support to the industry.
Moreover, Hyderabad boasts a skilled workforce, with a strong pipeline of pharmacists, biotechnologists, and chemists graduating from universities every year. The city’s infrastructure, logistics connectivity, and policy support have made it attractive for pharmaceutical exports and R&D investments.
Economic Impact
Hyderabad contributes significantly to India’s pharmaceutical export earnings. Telangana accounts for a major share of India’s bulk drug and formulation exports, and Hyderabad is at the core of this activity. The pharmaceutical sector also generates thousands of jobs, ranging from lab technicians to regulatory experts.
The Telangana government continues to support the industry through policy frameworks like the Life Sciences Policy, with a vision to make Hyderabad the “Life Sciences Capital of the World” by 2030.
Future Outlook
With continued investment in infrastructure, innovation, and workforce development, Hyderabad is poised to maintain and expand its dominance in the pharma and biotech sectors. The proposed Pharma City, a massive 19,000-acre industrial park, aims to further strengthen Hyderabad’s position as the leading center for pharmaceutical production and research.
This futuristic industrial cluster is expected to attract both domestic and foreign investors, providing a sustainable and integrated ecosystem for pharma manufacturing.